Survival according to different factors between the consolidation chemotherapy group and the concurrent chemoradiotherapy alone group
| Pathologic factors/group | N | Disease-free survival | P value | Overall survival | P value | ||
| Group A* | Group B† | Group A* | Group B† | ||||
| One positive LN | 65 | 88.9% | 92.3% | 0.74 | 90.2% | 92.3% | 0.99 |
| One positive LN+LVSI | 50 | 86.8% | 94.1% | 0.49 | 90.9% | 91.7% | 0.67 |
| One positive LN+≥1/3 stromal invasion | 53 | 87.6% | 95.0% | 0.43 | 91.4% | 92.9% | 0.64 |
| One positive LN+non-SCC | 11 | 71.4% | 100.0% | 0.27 | 71.4% | 100.0% | 0.27 |
| One positive LN+LVSI+≥1/3 stromal invasion | 46 | 84.9% | 94.1% | 0.41 | 89.7% | 91.7% | 0.61 |
| ≥2 positive LN | 73 | 68.0% | 55.9% | 0.10 | 73.9% | 58.0% | 0.08 |
| ≥2 positive LN+LVSI | 59 | 65.7% | 43.2% | 0.01 | 70.7% | 44.4% | 0.02 |
| ≥2 positive LN+≥1/3 stromal invasion | 62 | 64.2% | 39.7% | 0.015 | 70.4% | 42.5% | 0.016 |
| ≥2 positive LN+positive PALN | 19 | 51.9% | 16.7% | 0.08 | 57.1% | 22.2% | 0.11 |
| ≥2 positive LN+non-SCC | 20 | 66.7% | 40.0% | 0.21 | 62.9% | 30.0% | 0.26 |
| ≥3 positive LN | 49 | 69.7% | 40.0% | 0.03 | 70.8% | 43.2% | 0.048 |
*Group A: consolidation chemotherapy group.
†Group B: concurrent chemoradiotherapy alone group.
CILN, common iliac lymph node; LN, lymph nodes; LVSI, lymphovascular space invasion; PALN, para-aortic lymph node; SCC, squamous cell carcinoma.